View in EDS HTML Full Text PDF Full Text

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.

Saved in:
Bibliographic Details
Title: Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
Authors: Blauvelt A; Blauvelt Consulting, LLC, Annapolis, MD, USA., Kircik L; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana University School of Medicine, Indianapolis, IN, USA., Schlesinger T; Clinical Research Center of the Carolinas, Charleston, SC, USA.; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Pierce E; Eli Lilly and Company, Indianapolis, IN, USA., Burge R; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA., Behling M; Syneos Health, Morrisville, NC, USA., Atwater AR; Eli Lilly and Company, Indianapolis, IN, USA., ElMaraghy H; Eli Lilly and Company, Indianapolis, IN, USA., Armstrong A; Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
Source: The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2442720. Date of Electronic Publication: 2025 Jan 06.
Publication Type: Journal Article
Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39761965
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Blauvelt+A%22">Blauvelt A</searchLink>; Blauvelt Consulting, LLC, Annapolis, MD, USA.<br /><searchLink fieldCode="AU" term="%22Kircik+L%22">Kircik L</searchLink>; Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana University School of Medicine, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Schlesinger+T%22">Schlesinger T</searchLink>; Clinical Research Center of the Carolinas, Charleston, SC, USA.; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Pierce+E%22">Pierce E</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Burge+R%22">Burge R</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.; University of Cincinnati, Cincinnati, OH, USA.<br /><searchLink fieldCode="AU" term="%22Behling+M%22">Behling M</searchLink>; Syneos Health, Morrisville, NC, USA.<br /><searchLink fieldCode="AU" term="%22Atwater+AR%22">Atwater AR</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22ElMaraghy+H%22">ElMaraghy H</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Armstrong+A%22">Armstrong A</searchLink>; Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228918133%22">The Journal of dermatological treatment</searchLink> [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2442720. <i>Date of Electronic Publication: </i>2025 Jan 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Informa+Healthcare%22">Informa Healthcare </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8918133 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-1753 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209546634%22">09546634 </searchLink><i>NLM ISO Abbreviation: </i>J Dermatolog Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39761965
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/09546634.2024.2442720
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2442720
    Titles:
      – TitleFull: Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Blauvelt A
      – PersonEntity:
          Name:
            NameFull: Kircik L
      – PersonEntity:
          Name:
            NameFull: Schlesinger T
      – PersonEntity:
          Name:
            NameFull: Pierce E
      – PersonEntity:
          Name:
            NameFull: Burge R
      – PersonEntity:
          Name:
            NameFull: Behling M
      – PersonEntity:
          Name:
            NameFull: Atwater AR
      – PersonEntity:
          Name:
            NameFull: ElMaraghy H
      – PersonEntity:
          Name:
            NameFull: Armstrong A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1471-1753
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: The Journal of dermatological treatment
              Type: main
ResultId 1